Helicobacter Pylori Eradication With a New Sequential Treatment
Helicobacter Pylori Eradication With a New Sequential Treatment
Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are
 disappointing, and studies from several countries confirm this poor performance. The study
 aimed to assess the eradication rate of a new sequential treatment regimen compared with
 conventional triple therapy for the eradication of H. pylori infection.
One thousand and forty-nine dyspeptic patients were studied prospectively. H. pylori-infected
 patients were randomized to receive 10-day sequential therapy [rabeprazole (20 mg twice
 daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by rabeprazole (20
 mg), clarithromycin (500 mg) and tinidazole (500 mg, all twice daily for the remaining 5
 days] or standard 7-day therapy [corrected] [rabeprazole (20 mg), clarithromycin (500 mg) and
 amoxicillin (1 g), all twice daily]. H. pylori status was assessed by histology, rapid urease
 test and 13C-urea breath test at baseline and 6 weeks or more after completion of treatment.
Inclusion Criteria:

 -  Presence of active H. pylori infection

 -  Age >18 years

 Exclusion Criteria:

 -  Allergy to drug administered

 -  Liver or kidney failure

 -  Pregnancy

 -  Previous treatment for H. pylori infection